B-Cell Lymphoma

The aim of the DIRECT Study is to establish a robust pipeline to identify those patients with high-grade B cell lymphoma most suitable for novel agent clinical trials based upon genomic subtype and an integrated response evaluation determined early in first-line therapy.

This will be done by integrating data and samples collected from patients undergoing standard of care treatment for high-grade B cell lymphoma.

The trial is being funded jointly by AstraZeneca and the Cancer Research UK Cambridge Centre as well as being a flagship trial for MFICM. The trial currently has a total of 198 patients recruited over 5 sites as follows:

Addenbrooke’s Hospital                                                         39

University Hospitals Leicester                                              43

Norfolk & Norwich University Hospital                              34

Northwest Anglia NHS Foundation Trust                          19

Nottingham University Hospital                                          38

West Suffolk Hospital                                                             25

Total                                                                                           198 participants

* numbers correct as of 03/09/2024

Data will be integrated from

1. Clinical risk factors from the International Prognostic Index (IPI)
2. Up-front genomic subtype based on molecular profiling of diagnostic biopsy
3. Serial ctDNA monitoring during treatment.
4. Radiological response imaging

Clinical trial registration